Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prognostic Significance of ctDNA in HL
Sponsor: Interni hematologicka klinika FNKV
Summary
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.
Official title: Prognostic Significance of Circulating Tumor DNA in Hodgkin Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2022-01-02
Completion Date
2027-12-31
Last Updated
2024-02-16
Healthy Volunteers
Not specified
Conditions
Locations (5)
University Hospital Hradec Kralove
Hradec Králové, Czechia
University Hospital Olomouc
Olomouc, Czechia
University Hospital Kralovske Vinohrady
Prague, Czechia
Charles University
Prague, Czechia
General University Hospital
Prague, Czechia